The use of Ozurdex intravitreal implant to treat post-RVO macular edema

Cover Page


Cite item

Full Text

Abstract

This reports on the efficacy and safety of Ozurdex intravitreal implant (1 up to 3 injections) in different types of retinal vein occlusion (RVO) was based on examination data of 26 patients, referred to the ophthalmology clinic of the First Pavlov Sate Medical University of St. Petersburg. Ophthalmic examination, fluorescein angiography, optical coherence tomography, fundus photography, and microperimetry were all routinely used to follow these patients. Intravitreal injections of Ozurdex in post-RVO macular edema resulted in a statistically significant visual acuity improvement and decrease in retinal thickness. No cases of lens opacity progression were observed. Ocular hypertension was transient and controlled by topical IOP-lowering therapy. In cases of ischemic central retinal vein occlusions, to prevent and treat neovascular complications it is necessary to resort to additional treatment methods.

About the authors

Svetlana Nikolaevna Tultseva

First Pavlov Sate Medical University of St. Petersburg

Email: tultceva@yandex.ru
MD, PhD, assistant professor. Ophthalmology department

Pavel Andreevich Nechiporenko

First Pavlov Sate Medical University of St. Petersburg

Email: glaz@doctor.com
MD, PhD, assistant. Ophthalmology department

Aleksandra Ivanovna Titarenko

First Pavlov Sate Medical University of St. Petersburg

Email: aleksandra-titarenko@yandex.ru
resident. Ophthalmology department

References

  1. Augustin A., Loewenstein A., Kuppermann B. D. Macular edema. General pathophysiology. Dev. Ophthalmol. 2010; 47: 10-26.
  2. Bhavsar A. R., Ip M. S., Glassman A. R. DRCRnet and the SCORE Study Groups. The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am. J. Ophthalmol. 2007; 144 (3): 454-56.
  3. Cekic O., Chang S., Tseng J. J. et al. Intravitreal triamcinolone treatment for macular edema associated with central retinal vein occlusion and hemiretinal vein occlusion. Retina. 2005; 25: 846-50.
  4. Chen S. D., Sundaram V., Lochhead J., Patel C. K. Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion. Am. J. Ophthalmol. 2006; 141: 876-83.
  5. Haller J. A. [et al.] Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010; 117 (6): 1134-46.
  6. Hayreh S. S., Podhajsky P. A., Zimmerman M. B. Natural history of visual outcome in central retinal vein occlusion. Ophthalmology. 2011; 118 (1): 119-33.
  7. Ip M. S., Gottlieb J. L., Kahana A. et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch. Ophthalmol. 2004; 122: 1131-36.
  8. Jonas J. B., Akkoyun I., Kamppeter B. et al. Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide. Eye (Lond). 2005; 19: 65-71.
  9. Joussen A. M., Murata T., Tsujikawa A. et al. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am. J. Pathol. 2001;158: 147-52.
  10. Krepler K., Ergun E., Sacu S. et al. Intravitreal triamcinolone acetonide in patients with macular edema due to central retinal vein occlusion. Acta. Ophthalmol. Scand. 2005; 83: 71-5.
  11. Luna J. D., Chan C. C., DerevjanikN. L. et al. Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: comparison with vascular endothelial growth factor, tumor necrosis factor alpha, and interleukin-1beta-mediated breakdown. J. Neurosci. Res. 1997; 49 (3): 268-80.
  12. Mahemuti A., Abudureheman K., Aihemaiti X. et al. Association of interleukin-6 and C-reactive protein genetic polymorphisms levels with venous thromboembolism. Chin. Med. J. (Engl.). 2012; 125 (22): 3997-4002.
  13. Mayer W. J., Wolf A., Kernt M. et al. Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion. Eye. 2013; 27: 816-22.
  14. McLeod D. S., Lefer D. J., Mergec C., Luttly G. A. Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid. Am. J. Pathol. 1995; 147: 642-53.
  15. Moisseiev E., Goldstein M., Waisbourd M. et al. Long-term evaluation of patients treated with dexamethasone intravitreal implant for macular edema due to retinal vein occlusion. Eye (Lond.). 2013; 27 (1): 65-71.
  16. Nehmé A., Edelman J. Dexamethasone inhibits high glucose-, TNF-alpha-, and IL-1beta-induced secretion of inflammatory and angiogenic mediators from retinal microvascular pericytes. Invest Ophthalmol. Vis. Sci. 2008; 49 (5): 2030-38.
  17. Noma H., Funatsu H., Mimura T. et al. Increase of vascular endothelial growth factor and interleukin-6 in the aqueous humour of patients with macular edema with and central vein occlusion. Acta. Ophthal. 2010; 88 (6): 646-51.
  18. Noma H., Funatsu H., Harino S. et al. Vitreous inflammatory factors in macular edema with central retinal vein occlusion // Jpn. J. Ophthalmol, 2011; 55 (3): 248-255.
  19. Reibaldi M., Russo A., Zagari M. et al. Resolution of persistent cystoid macular edema due to central retinal vein occlusion in a vitrectomized eye following intravitreal implant of dexamethasone 0.7 mg. Case. Rep. Ophthalmol. 2012; 3 (1): 30-4.
  20. Rogers S. L., Mclntosh R. L., Cheung N. et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010; 117 (2): 313-19.
  21. Rogers S. L., Mclntosh R. L., Lim L., Mitchell P. et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010; 117 (6): 1094-1101.
  22. The SCORE Study Research Group, Ip M. S., Scott I. U. et al. A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone With Observation to Treat Vision Loss Associated With Macular Edema Secondary to Central Retinal Vein Occlusion The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 5. Arch. Ophthalmol. 2009; 127 (9): 1101-14.
  23. Williamson T. H., O’Donnell A. Intravitreal triamcinolone acetonide for cystoid macular edema in nonischemic central retinal vein occlusion. Am. J. Ophthalmol. 2005; 139: 860-66.
  24. Yanoff M., Fine B. S., Brucker A. J. et al. Pathology of human cystoid macular edema. Surv. Ophthalmol. 1984; Supll. 28: 505-511.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Tultseva S.N., Nechiporenko P.A., Titarenko A.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-65574 от 04 мая 2016 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies